nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—Nateglinide—type 2 diabetes mellitus	0.376	1	CrCtD
Bortezomib—Aspartame—Nateglinide—type 2 diabetes mellitus	0.057	0.308	CrCrCtD
Bortezomib—Lacosamide—Nateglinide—type 2 diabetes mellitus	0.057	0.308	CrCrCtD
Bortezomib—CYP1A2—type 2 diabetes mellitus	0.0557	0.602	CbGaD
Bortezomib—CYP3A4—type 2 diabetes mellitus	0.0369	0.398	CbGaD
Bortezomib—Nateglinide—Ramipril—type 2 diabetes mellitus	0.0365	0.197	CrCrCtD
Bortezomib—Aspartame—Ramipril—type 2 diabetes mellitus	0.0347	0.187	CrCrCtD
Bortezomib—PTGS1—Pioglitazone—type 2 diabetes mellitus	0.00949	0.0492	CbGbCtD
Bortezomib—PTGS1—Chlorpropamide—type 2 diabetes mellitus	0.00949	0.0492	CbGbCtD
Bortezomib—PTGS1—Rosiglitazone—type 2 diabetes mellitus	0.00876	0.0454	CbGbCtD
Bortezomib—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.00758	0.0393	CbGbCtD
Bortezomib—PTGS1—Nateglinide—type 2 diabetes mellitus	0.00719	0.0373	CbGbCtD
Bortezomib—PTGS1—Irbesartan—type 2 diabetes mellitus	0.0069	0.0357	CbGbCtD
Bortezomib—CYP2C8—Repaglinide—type 2 diabetes mellitus	0.00606	0.0314	CbGbCtD
Bortezomib—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.00548	0.0284	CbGbCtD
Bortezomib—CYP2C19—Gliclazide—type 2 diabetes mellitus	0.00541	0.028	CbGbCtD
Bortezomib—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.00529	0.0274	CbGbCtD
Bortezomib—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.00506	0.0262	CbGbCtD
Bortezomib—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.00488	0.0253	CbGbCtD
Bortezomib—CYP2C9—Glipizide—type 2 diabetes mellitus	0.00483	0.025	CbGbCtD
Bortezomib—CYP2C19—Pioglitazone—type 2 diabetes mellitus	0.0046	0.0238	CbGbCtD
Bortezomib—CYP2C19—Chlorpropamide—type 2 diabetes mellitus	0.0046	0.0238	CbGbCtD
Bortezomib—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.00449	0.0233	CbGbCtD
Bortezomib—CYP2C19—Rosiglitazone—type 2 diabetes mellitus	0.00424	0.022	CbGbCtD
Bortezomib—CYP2C19—Tolbutamide—type 2 diabetes mellitus	0.0041	0.0212	CbGbCtD
Bortezomib—CYP2C8—Irbesartan—type 2 diabetes mellitus	0.00398	0.0206	CbGbCtD
Bortezomib—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.00391	0.0203	CbGbCtD
Bortezomib—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.00382	0.0198	CbGbCtD
Bortezomib—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.00382	0.0198	CbGbCtD
Bortezomib—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.00353	0.0183	CbGbCtD
Bortezomib—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.00349	0.0181	CbGbCtD
Bortezomib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00345	0.0179	CbGbCtD
Bortezomib—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.00341	0.0176	CbGbCtD
Bortezomib—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00322	0.0167	CbGbCtD
Bortezomib—CYP2C9—Valsartan—type 2 diabetes mellitus	0.00311	0.0161	CbGbCtD
Bortezomib—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.00308	0.016	CbGbCtD
Bortezomib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00307	0.0159	CbGbCtD
Bortezomib—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00291	0.0151	CbGbCtD
Bortezomib—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.0029	0.015	CbGbCtD
Bortezomib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00281	0.0146	CbGbCtD
Bortezomib—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.00278	0.0144	CbGbCtD
Bortezomib—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00265	0.0137	CbGbCtD
Bortezomib—CYP2C8—Losartan—type 2 diabetes mellitus	0.00256	0.0133	CbGbCtD
Bortezomib—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00254	0.0132	CbGbCtD
Bortezomib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00246	0.0127	CbGbCtD
Bortezomib—CYP2C19—Glyburide—type 2 diabetes mellitus	0.00235	0.0122	CbGbCtD
Bortezomib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00222	0.0115	CbGbCtD
Bortezomib—CYP2C19—Losartan—type 2 diabetes mellitus	0.00215	0.0111	CbGbCtD
Bortezomib—CYP1A2—Losartan—type 2 diabetes mellitus	0.00199	0.0103	CbGbCtD
Bortezomib—CYP2C9—Glyburide—type 2 diabetes mellitus	0.00196	0.0101	CbGbCtD
Bortezomib—CYP2C9—Losartan—type 2 diabetes mellitus	0.00179	0.00927	CbGbCtD
Bortezomib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00168	0.00872	CbGbCtD
Bortezomib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00161	0.00836	CbGbCtD
Bortezomib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00161	0.00836	CbGbCtD
Bortezomib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00153	0.00791	CbGbCtD
Bortezomib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00114	0.00589	CbGbCtD
Bortezomib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00104	0.00539	CbGbCtD
Bortezomib—PSMD1—islet of Langerhans—type 2 diabetes mellitus	0.000705	0.0297	CbGeAlD
Bortezomib—CTSG—cardiovascular system—type 2 diabetes mellitus	0.000633	0.0267	CbGeAlD
Bortezomib—PSMD2—islet of Langerhans—type 2 diabetes mellitus	0.000625	0.0263	CbGeAlD
Bortezomib—PSMB8—islet of Langerhans—type 2 diabetes mellitus	0.000621	0.0262	CbGeAlD
Bortezomib—PSMA1—cardiovascular system—type 2 diabetes mellitus	0.000608	0.0256	CbGeAlD
Bortezomib—PSMD1—retina—type 2 diabetes mellitus	0.000603	0.0254	CbGeAlD
Bortezomib—PSMD1—nephron tubule—type 2 diabetes mellitus	0.000568	0.0239	CbGeAlD
Bortezomib—CTSG—adipose tissue—type 2 diabetes mellitus	0.000558	0.0235	CbGeAlD
Bortezomib—PSMB5—islet of Langerhans—type 2 diabetes mellitus	0.000548	0.0231	CbGeAlD
Bortezomib—PSMA1—adipose tissue—type 2 diabetes mellitus	0.000536	0.0226	CbGeAlD
Bortezomib—PSMD2—retina—type 2 diabetes mellitus	0.000534	0.0225	CbGeAlD
Bortezomib—PSMD2—nephron tubule—type 2 diabetes mellitus	0.000503	0.0212	CbGeAlD
Bortezomib—PSMD1—pancreas—type 2 diabetes mellitus	0.000496	0.0209	CbGeAlD
Bortezomib—PSMD1—cortex of kidney—type 2 diabetes mellitus	0.000486	0.0205	CbGeAlD
Bortezomib—PSMB1—islet of Langerhans—type 2 diabetes mellitus	0.000479	0.0202	CbGeAlD
Bortezomib—PSMB2—islet of Langerhans—type 2 diabetes mellitus	0.000468	0.0197	CbGeAlD
Bortezomib—PSMD2—cardiovascular system—type 2 diabetes mellitus	0.000452	0.019	CbGeAlD
Bortezomib—PSMD1—adipose tissue—type 2 diabetes mellitus	0.00045	0.0189	CbGeAlD
Bortezomib—PSMD2—kidney—type 2 diabetes mellitus	0.000442	0.0186	CbGeAlD
Bortezomib—PSMB5—nephron tubule—type 2 diabetes mellitus	0.000442	0.0186	CbGeAlD
Bortezomib—PSMD2—pancreas—type 2 diabetes mellitus	0.000439	0.0185	CbGeAlD
Bortezomib—PSMB8—pancreas—type 2 diabetes mellitus	0.000436	0.0184	CbGeAlD
Bortezomib—PSMD2—cortex of kidney—type 2 diabetes mellitus	0.000431	0.0181	CbGeAlD
Bortezomib—PSMB8—cortex of kidney—type 2 diabetes mellitus	0.000428	0.018	CbGeAlD
Bortezomib—PSMB2—retina—type 2 diabetes mellitus	0.0004	0.0168	CbGeAlD
Bortezomib—PSMD2—adipose tissue—type 2 diabetes mellitus	0.000398	0.0168	CbGeAlD
Bortezomib—PSMB8—adipose tissue—type 2 diabetes mellitus	0.000396	0.0167	CbGeAlD
Bortezomib—PSMB1—nephron tubule—type 2 diabetes mellitus	0.000386	0.0163	CbGeAlD
Bortezomib—PSMB5—pancreas—type 2 diabetes mellitus	0.000386	0.0162	CbGeAlD
Bortezomib—PSMB5—cortex of kidney—type 2 diabetes mellitus	0.000378	0.0159	CbGeAlD
Bortezomib—PSMB2—nephron tubule—type 2 diabetes mellitus	0.000377	0.0159	CbGeAlD
Bortezomib—PSMA1—liver—type 2 diabetes mellitus	0.000376	0.0158	CbGeAlD
Bortezomib—Nateglinide—ABCC8—type 2 diabetes mellitus	0.000364	0.415	CrCbGaD
Bortezomib—PSMB5—adipose tissue—type 2 diabetes mellitus	0.00035	0.0147	CbGeAlD
Bortezomib—PSMB1—cardiovascular system—type 2 diabetes mellitus	0.000347	0.0146	CbGeAlD
Bortezomib—PSMB1—kidney—type 2 diabetes mellitus	0.000339	0.0143	CbGeAlD
Bortezomib—PSMB2—cardiovascular system—type 2 diabetes mellitus	0.000338	0.0142	CbGeAlD
Bortezomib—PSMB1—pancreas—type 2 diabetes mellitus	0.000337	0.0142	CbGeAlD
Bortezomib—PSMB2—kidney—type 2 diabetes mellitus	0.000331	0.0139	CbGeAlD
Bortezomib—PSMB1—cortex of kidney—type 2 diabetes mellitus	0.00033	0.0139	CbGeAlD
Bortezomib—PSMB2—pancreas—type 2 diabetes mellitus	0.000329	0.0138	CbGeAlD
Bortezomib—SLC31A1—nephron tubule—type 2 diabetes mellitus	0.000326	0.0137	CbGeAlD
Bortezomib—PSMB2—cortex of kidney—type 2 diabetes mellitus	0.000322	0.0136	CbGeAlD
Bortezomib—PSMD1—liver—type 2 diabetes mellitus	0.000315	0.0133	CbGeAlD
Bortezomib—PSMB1—adipose tissue—type 2 diabetes mellitus	0.000306	0.0129	CbGeAlD
Bortezomib—PSMB2—adipose tissue—type 2 diabetes mellitus	0.000298	0.0126	CbGeAlD
Bortezomib—SLC31A1—kidney—type 2 diabetes mellitus	0.000287	0.0121	CbGeAlD
Bortezomib—PSMD2—liver—type 2 diabetes mellitus	0.000279	0.0118	CbGeAlD
Bortezomib—SLC31A1—cortex of kidney—type 2 diabetes mellitus	0.000279	0.0118	CbGeAlD
Bortezomib—PSMB8—liver—type 2 diabetes mellitus	0.000278	0.0117	CbGeAlD
Bortezomib—SLC31A1—adipose tissue—type 2 diabetes mellitus	0.000258	0.0109	CbGeAlD
Bortezomib—Nateglinide—KCNJ11—type 2 diabetes mellitus	0.000256	0.292	CrCbGaD
Bortezomib—PTGS1—artery—type 2 diabetes mellitus	0.000252	0.0106	CbGeAlD
Bortezomib—PSMB5—liver—type 2 diabetes mellitus	0.000245	0.0103	CbGeAlD
Bortezomib—PSMB1—liver—type 2 diabetes mellitus	0.000214	0.00903	CbGeAlD
Bortezomib—PTGS1—endothelium—type 2 diabetes mellitus	0.000212	0.00895	CbGeAlD
Bortezomib—PSMB2—liver—type 2 diabetes mellitus	0.000209	0.00881	CbGeAlD
Bortezomib—PSMD2—Rosiglitazone—Pioglitazone—type 2 diabetes mellitus	0.000201	0.109	CbGdCrCtD
Bortezomib—SLC31A1—liver—type 2 diabetes mellitus	0.000181	0.00763	CbGeAlD
Bortezomib—PSMD2—Tolazamide—Tolbutamide—type 2 diabetes mellitus	0.000156	0.0848	CbGdCrCtD
Bortezomib—PSMD2—Tolazamide—Glipizide—type 2 diabetes mellitus	0.000156	0.0848	CbGdCrCtD
Bortezomib—PSMD2—Tolazamide—Gliclazide—type 2 diabetes mellitus	0.000156	0.0848	CbGdCrCtD
Bortezomib—PSMD2—Tolazamide—Chlorpropamide—type 2 diabetes mellitus	0.000143	0.0775	CbGdCrCtD
Bortezomib—Nateglinide—PPARG—type 2 diabetes mellitus	0.000142	0.162	CrCbGaD
Bortezomib—PSMD2—Tolbutamide—Glimepiride—type 2 diabetes mellitus	0.000133	0.0721	CbGdCrCtD
Bortezomib—PSMD2—Tolbutamide—Tolazamide—type 2 diabetes mellitus	0.000133	0.0721	CbGdCrCtD
Bortezomib—PSMD2—Tolbutamide—Gliclazide—type 2 diabetes mellitus	0.000126	0.0683	CbGdCrCtD
Bortezomib—PSMD2—Tolbutamide—Glipizide—type 2 diabetes mellitus	0.000126	0.0683	CbGdCrCtD
Bortezomib—PSMD2—Tolbutamide—Chlorpropamide—type 2 diabetes mellitus	0.000115	0.0625	CbGdCrCtD
Bortezomib—PSMD2—Tolazamide—Glyburide—type 2 diabetes mellitus	0.000108	0.0588	CbGdCrCtD
Bortezomib—CYP2C8—kidney—type 2 diabetes mellitus	0.000105	0.00444	CbGeAlD
Bortezomib—CYP1A1—kidney—type 2 diabetes mellitus	9.74e-05	0.0041	CbGeAlD
Bortezomib—CYP2C9—cardiovascular system—type 2 diabetes mellitus	9.57e-05	0.00403	CbGeAlD
Bortezomib—CYP1A1—adipose tissue—type 2 diabetes mellitus	8.77e-05	0.0037	CbGeAlD
Bortezomib—PTGS1—cardiovascular system—type 2 diabetes mellitus	8.74e-05	0.00368	CbGeAlD
Bortezomib—PTGS1—kidney—type 2 diabetes mellitus	8.55e-05	0.0036	CbGeAlD
Bortezomib—PTGS1—adipose tissue—type 2 diabetes mellitus	7.71e-05	0.00325	CbGeAlD
Bortezomib—CYP2C19—liver—type 2 diabetes mellitus	7.64e-05	0.00322	CbGeAlD
Bortezomib—CYP3A4—kidney—type 2 diabetes mellitus	7.14e-05	0.00301	CbGeAlD
Bortezomib—CYP2D6—kidney—type 2 diabetes mellitus	7.03e-05	0.00296	CbGeAlD
Bortezomib—CYP2C8—liver—type 2 diabetes mellitus	6.67e-05	0.00281	CbGeAlD
Bortezomib—CYP1A2—liver—type 2 diabetes mellitus	6.24e-05	0.00263	CbGeAlD
Bortezomib—CYP1A1—liver—type 2 diabetes mellitus	6.15e-05	0.00259	CbGeAlD
Bortezomib—Nateglinide—CYP3A4—type 2 diabetes mellitus	6.12e-05	0.0699	CrCbGaD
Bortezomib—CYP2C9—liver—type 2 diabetes mellitus	5.92e-05	0.00249	CbGeAlD
Bortezomib—PSMB8—Glipizide—Glimepiride—type 2 diabetes mellitus	5.35e-05	0.029	CbGdCrCtD
Bortezomib—PSMB8—Glipizide—Tolazamide—type 2 diabetes mellitus	5.35e-05	0.029	CbGdCrCtD
Bortezomib—Nateglinide—ALB—type 2 diabetes mellitus	5.34e-05	0.0609	CrCbGaD
Bortezomib—PSMB8—Glipizide—Gliclazide—type 2 diabetes mellitus	5.07e-05	0.0275	CbGdCrCtD
Bortezomib—PSMB8—Glipizide—Tolbutamide—type 2 diabetes mellitus	5.07e-05	0.0275	CbGdCrCtD
Bortezomib—PSMB8—Glipizide—Chlorpropamide—type 2 diabetes mellitus	4.64e-05	0.0251	CbGdCrCtD
Bortezomib—CYP3A4—liver—type 2 diabetes mellitus	4.52e-05	0.0019	CbGeAlD
Bortezomib—CYP2D6—liver—type 2 diabetes mellitus	4.44e-05	0.00187	CbGeAlD
Bortezomib—PSMB8—Glipizide—Glyburide—type 2 diabetes mellitus	3.51e-05	0.019	CbGdCrCtD
Bortezomib—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	1.66e-05	0.000237	CcSEcCtD
Bortezomib—Chest pain—Irbesartan—type 2 diabetes mellitus	1.66e-05	0.000237	CcSEcCtD
Bortezomib—Arthralgia—Irbesartan—type 2 diabetes mellitus	1.66e-05	0.000237	CcSEcCtD
Bortezomib—Myalgia—Irbesartan—type 2 diabetes mellitus	1.66e-05	0.000237	CcSEcCtD
Bortezomib—Shock—Metformin—type 2 diabetes mellitus	1.66e-05	0.000237	CcSEcCtD
Bortezomib—Insomnia—Orlistat—type 2 diabetes mellitus	1.66e-05	0.000236	CcSEcCtD
Bortezomib—Malaise—Losartan—type 2 diabetes mellitus	1.66e-05	0.000236	CcSEcCtD
Bortezomib—Anxiety—Irbesartan—type 2 diabetes mellitus	1.66e-05	0.000236	CcSEcCtD
Bortezomib—Hypersensitivity—Glyburide—type 2 diabetes mellitus	1.65e-05	0.000236	CcSEcCtD
Bortezomib—Nervous system disorder—Metformin—type 2 diabetes mellitus	1.65e-05	0.000236	CcSEcCtD
Bortezomib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	1.65e-05	0.000236	CcSEcCtD
Bortezomib—Dyspnoea—Valsartan—type 2 diabetes mellitus	1.65e-05	0.000236	CcSEcCtD
Bortezomib—Vertigo—Losartan—type 2 diabetes mellitus	1.65e-05	0.000235	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	1.65e-05	0.000235	CcSEcCtD
Bortezomib—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	1.65e-05	0.000235	CcSEcCtD
Bortezomib—Syncope—Losartan—type 2 diabetes mellitus	1.65e-05	0.000235	CcSEcCtD
Bortezomib—Paraesthesia—Orlistat—type 2 diabetes mellitus	1.64e-05	0.000235	CcSEcCtD
Bortezomib—Leukopenia—Losartan—type 2 diabetes mellitus	1.64e-05	0.000234	CcSEcCtD
Bortezomib—Discomfort—Irbesartan—type 2 diabetes mellitus	1.64e-05	0.000234	CcSEcCtD
Bortezomib—Skin disorder—Metformin—type 2 diabetes mellitus	1.64e-05	0.000234	CcSEcCtD
Bortezomib—Immune system disorder—Ramipril—type 2 diabetes mellitus	1.63e-05	0.000233	CcSEcCtD
Bortezomib—Hyperhidrosis—Metformin—type 2 diabetes mellitus	1.63e-05	0.000233	CcSEcCtD
Bortezomib—Dyspepsia—Valsartan—type 2 diabetes mellitus	1.63e-05	0.000233	CcSEcCtD
Bortezomib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	1.63e-05	0.000233	CcSEcCtD
Bortezomib—Dizziness—Bromocriptine—type 2 diabetes mellitus	1.62e-05	0.000232	CcSEcCtD
Bortezomib—Palpitations—Losartan—type 2 diabetes mellitus	1.62e-05	0.000231	CcSEcCtD
Bortezomib—Nausea—Glimepiride—type 2 diabetes mellitus	1.62e-05	0.000231	CcSEcCtD
Bortezomib—Arrhythmia—Ramipril—type 2 diabetes mellitus	1.62e-05	0.00023	CcSEcCtD
Bortezomib—Loss of consciousness—Losartan—type 2 diabetes mellitus	1.61e-05	0.00023	CcSEcCtD
Bortezomib—Nausea—Sitagliptin—type 2 diabetes mellitus	1.61e-05	0.00023	CcSEcCtD
Bortezomib—Dyspepsia—Orlistat—type 2 diabetes mellitus	1.61e-05	0.00023	CcSEcCtD
Bortezomib—Asthenia—Glyburide—type 2 diabetes mellitus	1.61e-05	0.00023	CcSEcCtD
Bortezomib—Decreased appetite—Valsartan—type 2 diabetes mellitus	1.61e-05	0.00023	CcSEcCtD
Bortezomib—Anorexia—Metformin—type 2 diabetes mellitus	1.61e-05	0.000229	CcSEcCtD
Bortezomib—Cough—Losartan—type 2 diabetes mellitus	1.6e-05	0.000229	CcSEcCtD
Bortezomib—Urticaria—Gliclazide—type 2 diabetes mellitus	1.6e-05	0.000229	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	1.6e-05	0.000228	CcSEcCtD
Bortezomib—Fatigue—Valsartan—type 2 diabetes mellitus	1.6e-05	0.000228	CcSEcCtD
Bortezomib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	1.59e-05	0.000227	CcSEcCtD
Bortezomib—Abdominal pain—Gliclazide—type 2 diabetes mellitus	1.59e-05	0.000227	CcSEcCtD
Bortezomib—Oedema—Irbesartan—type 2 diabetes mellitus	1.59e-05	0.000227	CcSEcCtD
Bortezomib—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	1.59e-05	0.000227	CcSEcCtD
Bortezomib—Decreased appetite—Orlistat—type 2 diabetes mellitus	1.59e-05	0.000227	CcSEcCtD
Bortezomib—Pruritus—Glyburide—type 2 diabetes mellitus	1.59e-05	0.000227	CcSEcCtD
Bortezomib—Mental disorder—Ramipril—type 2 diabetes mellitus	1.58e-05	0.000226	CcSEcCtD
Bortezomib—Constipation—Valsartan—type 2 diabetes mellitus	1.58e-05	0.000226	CcSEcCtD
Bortezomib—Infection—Irbesartan—type 2 diabetes mellitus	1.58e-05	0.000226	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	1.58e-05	0.000225	CcSEcCtD
Bortezomib—Fatigue—Orlistat—type 2 diabetes mellitus	1.58e-05	0.000225	CcSEcCtD
Bortezomib—Hypotension—Metformin—type 2 diabetes mellitus	1.58e-05	0.000225	CcSEcCtD
Bortezomib—Erythema—Ramipril—type 2 diabetes mellitus	1.57e-05	0.000225	CcSEcCtD
Bortezomib—Malnutrition—Ramipril—type 2 diabetes mellitus	1.57e-05	0.000225	CcSEcCtD
Bortezomib—Shock—Irbesartan—type 2 diabetes mellitus	1.57e-05	0.000223	CcSEcCtD
Bortezomib—Pain—Orlistat—type 2 diabetes mellitus	1.57e-05	0.000223	CcSEcCtD
Bortezomib—Arthralgia—Losartan—type 2 diabetes mellitus	1.56e-05	0.000223	CcSEcCtD
Bortezomib—Myalgia—Losartan—type 2 diabetes mellitus	1.56e-05	0.000223	CcSEcCtD
Bortezomib—Chest pain—Losartan—type 2 diabetes mellitus	1.56e-05	0.000223	CcSEcCtD
Bortezomib—Vomiting—Bromocriptine—type 2 diabetes mellitus	1.56e-05	0.000223	CcSEcCtD
Bortezomib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	1.56e-05	0.000223	CcSEcCtD
Bortezomib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	1.56e-05	0.000222	CcSEcCtD
Bortezomib—Anxiety—Losartan—type 2 diabetes mellitus	1.56e-05	0.000222	CcSEcCtD
Bortezomib—Tachycardia—Irbesartan—type 2 diabetes mellitus	1.55e-05	0.000222	CcSEcCtD
Bortezomib—Rash—Bromocriptine—type 2 diabetes mellitus	1.55e-05	0.000221	CcSEcCtD
Bortezomib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	1.55e-05	0.000221	CcSEcCtD
Bortezomib—Skin disorder—Irbesartan—type 2 diabetes mellitus	1.55e-05	0.000221	CcSEcCtD
Bortezomib—Discomfort—Losartan—type 2 diabetes mellitus	1.54e-05	0.00022	CcSEcCtD
Bortezomib—Dysgeusia—Ramipril—type 2 diabetes mellitus	1.54e-05	0.00022	CcSEcCtD
Bortezomib—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	1.54e-05	0.00022	CcSEcCtD
Bortezomib—Headache—Bromocriptine—type 2 diabetes mellitus	1.54e-05	0.00022	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	1.54e-05	0.000219	CcSEcCtD
Bortezomib—Diarrhoea—Glyburide—type 2 diabetes mellitus	1.54e-05	0.000219	CcSEcCtD
Bortezomib—Anorexia—Irbesartan—type 2 diabetes mellitus	1.52e-05	0.000217	CcSEcCtD
Bortezomib—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	1.52e-05	0.000216	CcSEcCtD
Bortezomib—Paraesthesia—Metformin—type 2 diabetes mellitus	1.52e-05	0.000216	CcSEcCtD
Bortezomib—Muscle spasms—Ramipril—type 2 diabetes mellitus	1.51e-05	0.000216	CcSEcCtD
Bortezomib—Confusional state—Losartan—type 2 diabetes mellitus	1.51e-05	0.000216	CcSEcCtD
Bortezomib—Feeling abnormal—Orlistat—type 2 diabetes mellitus	1.51e-05	0.000215	CcSEcCtD
Bortezomib—Dyspnoea—Metformin—type 2 diabetes mellitus	1.5e-05	0.000215	CcSEcCtD
Bortezomib—Oedema—Losartan—type 2 diabetes mellitus	1.5e-05	0.000214	CcSEcCtD
Bortezomib—Anaphylactic shock—Losartan—type 2 diabetes mellitus	1.5e-05	0.000214	CcSEcCtD
Bortezomib—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	1.5e-05	0.000214	CcSEcCtD
Bortezomib—Infection—Losartan—type 2 diabetes mellitus	1.49e-05	0.000212	CcSEcCtD
Bortezomib—Hypotension—Irbesartan—type 2 diabetes mellitus	1.49e-05	0.000212	CcSEcCtD
Bortezomib—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	1.49e-05	0.000212	CcSEcCtD
Bortezomib—Dyspepsia—Metformin—type 2 diabetes mellitus	1.49e-05	0.000212	CcSEcCtD
Bortezomib—Tremor—Ramipril—type 2 diabetes mellitus	1.48e-05	0.00021	CcSEcCtD
Bortezomib—Shock—Losartan—type 2 diabetes mellitus	1.47e-05	0.00021	CcSEcCtD
Bortezomib—Urticaria—Valsartan—type 2 diabetes mellitus	1.47e-05	0.00021	CcSEcCtD
Bortezomib—Nervous system disorder—Losartan—type 2 diabetes mellitus	1.47e-05	0.00021	CcSEcCtD
Bortezomib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	1.47e-05	0.000209	CcSEcCtD
Bortezomib—Decreased appetite—Metformin—type 2 diabetes mellitus	1.47e-05	0.000209	CcSEcCtD
Bortezomib—Abdominal pain—Valsartan—type 2 diabetes mellitus	1.46e-05	0.000209	CcSEcCtD
Bortezomib—Tachycardia—Losartan—type 2 diabetes mellitus	1.46e-05	0.000209	CcSEcCtD
Bortezomib—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	1.46e-05	0.000208	CcSEcCtD
Bortezomib—Nausea—Bromocriptine—type 2 diabetes mellitus	1.46e-05	0.000208	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	1.46e-05	0.000208	CcSEcCtD
Bortezomib—Fatigue—Metformin—type 2 diabetes mellitus	1.45e-05	0.000208	CcSEcCtD
Bortezomib—Urticaria—Orlistat—type 2 diabetes mellitus	1.45e-05	0.000207	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	1.45e-05	0.000207	CcSEcCtD
Bortezomib—Hyperhidrosis—Losartan—type 2 diabetes mellitus	1.45e-05	0.000207	CcSEcCtD
Bortezomib—Abdominal pain—Orlistat—type 2 diabetes mellitus	1.45e-05	0.000206	CcSEcCtD
Bortezomib—Body temperature increased—Orlistat—type 2 diabetes mellitus	1.45e-05	0.000206	CcSEcCtD
Bortezomib—Asthenia—Gliclazide—type 2 diabetes mellitus	1.45e-05	0.000206	CcSEcCtD
Bortezomib—Agitation—Ramipril—type 2 diabetes mellitus	1.45e-05	0.000206	CcSEcCtD
Bortezomib—Constipation—Metformin—type 2 diabetes mellitus	1.44e-05	0.000206	CcSEcCtD
Bortezomib—Angioedema—Ramipril—type 2 diabetes mellitus	1.44e-05	0.000205	CcSEcCtD
Bortezomib—Paraesthesia—Irbesartan—type 2 diabetes mellitus	1.43e-05	0.000204	CcSEcCtD
Bortezomib—Anorexia—Losartan—type 2 diabetes mellitus	1.43e-05	0.000204	CcSEcCtD
Bortezomib—Vomiting—Glyburide—type 2 diabetes mellitus	1.43e-05	0.000204	CcSEcCtD
Bortezomib—Pruritus—Gliclazide—type 2 diabetes mellitus	1.43e-05	0.000204	CcSEcCtD
Bortezomib—Malaise—Ramipril—type 2 diabetes mellitus	1.42e-05	0.000203	CcSEcCtD
Bortezomib—Dyspnoea—Irbesartan—type 2 diabetes mellitus	1.42e-05	0.000202	CcSEcCtD
Bortezomib—Rash—Glyburide—type 2 diabetes mellitus	1.42e-05	0.000202	CcSEcCtD
Bortezomib—Dermatitis—Glyburide—type 2 diabetes mellitus	1.41e-05	0.000202	CcSEcCtD
Bortezomib—Vertigo—Ramipril—type 2 diabetes mellitus	1.41e-05	0.000202	CcSEcCtD
Bortezomib—Syncope—Ramipril—type 2 diabetes mellitus	1.41e-05	0.000201	CcSEcCtD
Bortezomib—Leukopenia—Ramipril—type 2 diabetes mellitus	1.41e-05	0.000201	CcSEcCtD
Bortezomib—Headache—Glyburide—type 2 diabetes mellitus	1.41e-05	0.000201	CcSEcCtD
Bortezomib—Dyspepsia—Irbesartan—type 2 diabetes mellitus	1.4e-05	0.0002	CcSEcCtD
Bortezomib—Hypotension—Losartan—type 2 diabetes mellitus	1.4e-05	0.0002	CcSEcCtD
Bortezomib—Palpitations—Ramipril—type 2 diabetes mellitus	1.39e-05	0.000198	CcSEcCtD
Bortezomib—Feeling abnormal—Metformin—type 2 diabetes mellitus	1.39e-05	0.000198	CcSEcCtD
Bortezomib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	1.38e-05	0.000197	CcSEcCtD
Bortezomib—Loss of consciousness—Ramipril—type 2 diabetes mellitus	1.38e-05	0.000197	CcSEcCtD
Bortezomib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	1.38e-05	0.000197	CcSEcCtD
Bortezomib—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	1.38e-05	0.000197	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	1.37e-05	0.000196	CcSEcCtD
Bortezomib—Cough—Ramipril—type 2 diabetes mellitus	1.37e-05	0.000196	CcSEcCtD
Bortezomib—Fatigue—Irbesartan—type 2 diabetes mellitus	1.37e-05	0.000196	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	1.37e-05	0.000195	CcSEcCtD
Bortezomib—Hypersensitivity—Valsartan—type 2 diabetes mellitus	1.37e-05	0.000195	CcSEcCtD
Bortezomib—Convulsion—Ramipril—type 2 diabetes mellitus	1.36e-05	0.000195	CcSEcCtD
Bortezomib—Constipation—Irbesartan—type 2 diabetes mellitus	1.36e-05	0.000194	CcSEcCtD
Bortezomib—Pain—Irbesartan—type 2 diabetes mellitus	1.36e-05	0.000194	CcSEcCtD
Bortezomib—Insomnia—Losartan—type 2 diabetes mellitus	1.36e-05	0.000193	CcSEcCtD
Bortezomib—Hypersensitivity—Orlistat—type 2 diabetes mellitus	1.35e-05	0.000192	CcSEcCtD
Bortezomib—Paraesthesia—Losartan—type 2 diabetes mellitus	1.35e-05	0.000192	CcSEcCtD
Bortezomib—Urticaria—Metformin—type 2 diabetes mellitus	1.34e-05	0.000191	CcSEcCtD
Bortezomib—Chest pain—Ramipril—type 2 diabetes mellitus	1.34e-05	0.000191	CcSEcCtD
Bortezomib—Myalgia—Ramipril—type 2 diabetes mellitus	1.34e-05	0.000191	CcSEcCtD
Bortezomib—Arthralgia—Ramipril—type 2 diabetes mellitus	1.34e-05	0.000191	CcSEcCtD
Bortezomib—Dyspnoea—Losartan—type 2 diabetes mellitus	1.34e-05	0.000191	CcSEcCtD
Bortezomib—Anxiety—Ramipril—type 2 diabetes mellitus	1.34e-05	0.000191	CcSEcCtD
Bortezomib—Nausea—Glyburide—type 2 diabetes mellitus	1.33e-05	0.00019	CcSEcCtD
Bortezomib—Abdominal pain—Metformin—type 2 diabetes mellitus	1.33e-05	0.00019	CcSEcCtD
Bortezomib—Dizziness—Gliclazide—type 2 diabetes mellitus	1.33e-05	0.00019	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	1.33e-05	0.00019	CcSEcCtD
Bortezomib—Asthenia—Valsartan—type 2 diabetes mellitus	1.33e-05	0.00019	CcSEcCtD
Bortezomib—Discomfort—Ramipril—type 2 diabetes mellitus	1.32e-05	0.000189	CcSEcCtD
Bortezomib—Dyspepsia—Losartan—type 2 diabetes mellitus	1.32e-05	0.000188	CcSEcCtD
Bortezomib—Asthenia—Orlistat—type 2 diabetes mellitus	1.31e-05	0.000187	CcSEcCtD
Bortezomib—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	1.31e-05	0.000187	CcSEcCtD
Bortezomib—Pruritus—Valsartan—type 2 diabetes mellitus	1.31e-05	0.000187	CcSEcCtD
Bortezomib—Decreased appetite—Losartan—type 2 diabetes mellitus	1.3e-05	0.000186	CcSEcCtD
Bortezomib—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	1.3e-05	0.000186	CcSEcCtD
Bortezomib—Confusional state—Ramipril—type 2 diabetes mellitus	1.3e-05	0.000185	CcSEcCtD
Bortezomib—Pruritus—Orlistat—type 2 diabetes mellitus	1.3e-05	0.000185	CcSEcCtD
Bortezomib—Fatigue—Losartan—type 2 diabetes mellitus	1.29e-05	0.000184	CcSEcCtD
Bortezomib—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	1.29e-05	0.000183	CcSEcCtD
Bortezomib—Oedema—Ramipril—type 2 diabetes mellitus	1.29e-05	0.000183	CcSEcCtD
Bortezomib—Vomiting—Gliclazide—type 2 diabetes mellitus	1.28e-05	0.000183	CcSEcCtD
Bortezomib—Pain—Losartan—type 2 diabetes mellitus	1.28e-05	0.000183	CcSEcCtD
Bortezomib—Constipation—Losartan—type 2 diabetes mellitus	1.28e-05	0.000183	CcSEcCtD
Bortezomib—Rash—Gliclazide—type 2 diabetes mellitus	1.27e-05	0.000181	CcSEcCtD
Bortezomib—Dermatitis—Gliclazide—type 2 diabetes mellitus	1.27e-05	0.000181	CcSEcCtD
Bortezomib—Diarrhoea—Valsartan—type 2 diabetes mellitus	1.27e-05	0.000181	CcSEcCtD
Bortezomib—Urticaria—Irbesartan—type 2 diabetes mellitus	1.27e-05	0.00018	CcSEcCtD
Bortezomib—Shock—Ramipril—type 2 diabetes mellitus	1.26e-05	0.00018	CcSEcCtD
Bortezomib—Headache—Gliclazide—type 2 diabetes mellitus	1.26e-05	0.00018	CcSEcCtD
Bortezomib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	1.26e-05	0.00018	CcSEcCtD
Bortezomib—Abdominal pain—Irbesartan—type 2 diabetes mellitus	1.26e-05	0.00018	CcSEcCtD
Bortezomib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	1.26e-05	0.00018	CcSEcCtD
Bortezomib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	1.26e-05	0.000179	CcSEcCtD
Bortezomib—Tachycardia—Ramipril—type 2 diabetes mellitus	1.25e-05	0.000179	CcSEcCtD
Bortezomib—Diarrhoea—Orlistat—type 2 diabetes mellitus	1.25e-05	0.000179	CcSEcCtD
Bortezomib—Skin disorder—Ramipril—type 2 diabetes mellitus	1.25e-05	0.000178	CcSEcCtD
Bortezomib—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	1.24e-05	0.000177	CcSEcCtD
Bortezomib—Feeling abnormal—Losartan—type 2 diabetes mellitus	1.23e-05	0.000176	CcSEcCtD
Bortezomib—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	1.23e-05	0.000175	CcSEcCtD
Bortezomib—Dizziness—Valsartan—type 2 diabetes mellitus	1.23e-05	0.000175	CcSEcCtD
Bortezomib—Anorexia—Ramipril—type 2 diabetes mellitus	1.22e-05	0.000175	CcSEcCtD
Bortezomib—Dizziness—Orlistat—type 2 diabetes mellitus	1.21e-05	0.000173	CcSEcCtD
Bortezomib—Asthenia—Metformin—type 2 diabetes mellitus	1.21e-05	0.000173	CcSEcCtD
Bortezomib—Hypotension—Ramipril—type 2 diabetes mellitus	1.2e-05	0.000171	CcSEcCtD
Bortezomib—Nausea—Gliclazide—type 2 diabetes mellitus	1.2e-05	0.000171	CcSEcCtD
Bortezomib—Pruritus—Metformin—type 2 diabetes mellitus	1.19e-05	0.00017	CcSEcCtD
Bortezomib—Urticaria—Losartan—type 2 diabetes mellitus	1.19e-05	0.00017	CcSEcCtD
Bortezomib—Abdominal pain—Losartan—type 2 diabetes mellitus	1.18e-05	0.000169	CcSEcCtD
Bortezomib—Body temperature increased—Losartan—type 2 diabetes mellitus	1.18e-05	0.000169	CcSEcCtD
Bortezomib—Vomiting—Valsartan—type 2 diabetes mellitus	1.18e-05	0.000168	CcSEcCtD
Bortezomib—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	1.17e-05	0.000167	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	1.17e-05	0.000167	CcSEcCtD
Bortezomib—Rash—Valsartan—type 2 diabetes mellitus	1.17e-05	0.000167	CcSEcCtD
Bortezomib—Dermatitis—Valsartan—type 2 diabetes mellitus	1.17e-05	0.000166	CcSEcCtD
Bortezomib—Vomiting—Orlistat—type 2 diabetes mellitus	1.16e-05	0.000166	CcSEcCtD
Bortezomib—Insomnia—Ramipril—type 2 diabetes mellitus	1.16e-05	0.000166	CcSEcCtD
Bortezomib—Headache—Valsartan—type 2 diabetes mellitus	1.16e-05	0.000166	CcSEcCtD
Bortezomib—Diarrhoea—Metformin—type 2 diabetes mellitus	1.15e-05	0.000165	CcSEcCtD
Bortezomib—Rash—Orlistat—type 2 diabetes mellitus	1.15e-05	0.000165	CcSEcCtD
Bortezomib—Paraesthesia—Ramipril—type 2 diabetes mellitus	1.15e-05	0.000165	CcSEcCtD
Bortezomib—Dermatitis—Orlistat—type 2 diabetes mellitus	1.15e-05	0.000165	CcSEcCtD
Bortezomib—Headache—Orlistat—type 2 diabetes mellitus	1.15e-05	0.000164	CcSEcCtD
Bortezomib—Dyspnoea—Ramipril—type 2 diabetes mellitus	1.15e-05	0.000163	CcSEcCtD
Bortezomib—Asthenia—Irbesartan—type 2 diabetes mellitus	1.14e-05	0.000163	CcSEcCtD
Bortezomib—Dyspepsia—Ramipril—type 2 diabetes mellitus	1.13e-05	0.000161	CcSEcCtD
Bortezomib—Pruritus—Irbesartan—type 2 diabetes mellitus	1.13e-05	0.000161	CcSEcCtD
Bortezomib—Decreased appetite—Ramipril—type 2 diabetes mellitus	1.12e-05	0.000159	CcSEcCtD
Bortezomib—Dizziness—Metformin—type 2 diabetes mellitus	1.12e-05	0.000159	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	1.11e-05	0.000158	CcSEcCtD
Bortezomib—Fatigue—Ramipril—type 2 diabetes mellitus	1.11e-05	0.000158	CcSEcCtD
Bortezomib—Hypersensitivity—Losartan—type 2 diabetes mellitus	1.1e-05	0.000157	CcSEcCtD
Bortezomib—Nausea—Valsartan—type 2 diabetes mellitus	1.1e-05	0.000157	CcSEcCtD
Bortezomib—Constipation—Ramipril—type 2 diabetes mellitus	1.1e-05	0.000157	CcSEcCtD
Bortezomib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	1.09e-05	0.000155	CcSEcCtD
Bortezomib—Nausea—Orlistat—type 2 diabetes mellitus	1.09e-05	0.000155	CcSEcCtD
Bortezomib—Asthenia—Losartan—type 2 diabetes mellitus	1.08e-05	0.000153	CcSEcCtD
Bortezomib—Vomiting—Metformin—type 2 diabetes mellitus	1.07e-05	0.000153	CcSEcCtD
Bortezomib—Rash—Metformin—type 2 diabetes mellitus	1.06e-05	0.000152	CcSEcCtD
Bortezomib—Dermatitis—Metformin—type 2 diabetes mellitus	1.06e-05	0.000152	CcSEcCtD
Bortezomib—Pruritus—Losartan—type 2 diabetes mellitus	1.06e-05	0.000151	CcSEcCtD
Bortezomib—Feeling abnormal—Ramipril—type 2 diabetes mellitus	1.06e-05	0.000151	CcSEcCtD
Bortezomib—Headache—Metformin—type 2 diabetes mellitus	1.06e-05	0.000151	CcSEcCtD
Bortezomib—Dizziness—Irbesartan—type 2 diabetes mellitus	1.05e-05	0.00015	CcSEcCtD
Bortezomib—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	1.05e-05	0.00015	CcSEcCtD
Bortezomib—Diarrhoea—Losartan—type 2 diabetes mellitus	1.03e-05	0.000146	CcSEcCtD
Bortezomib—Urticaria—Ramipril—type 2 diabetes mellitus	1.02e-05	0.000146	CcSEcCtD
Bortezomib—Abdominal pain—Ramipril—type 2 diabetes mellitus	1.02e-05	0.000145	CcSEcCtD
Bortezomib—Body temperature increased—Ramipril—type 2 diabetes mellitus	1.02e-05	0.000145	CcSEcCtD
Bortezomib—Vomiting—Irbesartan—type 2 diabetes mellitus	1.01e-05	0.000144	CcSEcCtD
Bortezomib—Rash—Irbesartan—type 2 diabetes mellitus	1e-05	0.000143	CcSEcCtD
Bortezomib—Dermatitis—Irbesartan—type 2 diabetes mellitus	1e-05	0.000143	CcSEcCtD
Bortezomib—Nausea—Metformin—type 2 diabetes mellitus	1e-05	0.000143	CcSEcCtD
Bortezomib—Headache—Irbesartan—type 2 diabetes mellitus	9.98e-06	0.000142	CcSEcCtD
Bortezomib—Dizziness—Losartan—type 2 diabetes mellitus	9.91e-06	0.000141	CcSEcCtD
Bortezomib—Vomiting—Losartan—type 2 diabetes mellitus	9.53e-06	0.000136	CcSEcCtD
Bortezomib—Hypersensitivity—Ramipril—type 2 diabetes mellitus	9.47e-06	0.000135	CcSEcCtD
Bortezomib—Nausea—Irbesartan—type 2 diabetes mellitus	9.46e-06	0.000135	CcSEcCtD
Bortezomib—Rash—Losartan—type 2 diabetes mellitus	9.45e-06	0.000135	CcSEcCtD
Bortezomib—Dermatitis—Losartan—type 2 diabetes mellitus	9.44e-06	0.000135	CcSEcCtD
Bortezomib—Headache—Losartan—type 2 diabetes mellitus	9.39e-06	0.000134	CcSEcCtD
Bortezomib—Asthenia—Ramipril—type 2 diabetes mellitus	9.22e-06	0.000132	CcSEcCtD
Bortezomib—Pruritus—Ramipril—type 2 diabetes mellitus	9.09e-06	0.00013	CcSEcCtD
Bortezomib—Nausea—Losartan—type 2 diabetes mellitus	8.9e-06	0.000127	CcSEcCtD
Bortezomib—Diarrhoea—Ramipril—type 2 diabetes mellitus	8.79e-06	0.000125	CcSEcCtD
Bortezomib—Dizziness—Ramipril—type 2 diabetes mellitus	8.5e-06	0.000121	CcSEcCtD
Bortezomib—Vomiting—Ramipril—type 2 diabetes mellitus	8.17e-06	0.000117	CcSEcCtD
Bortezomib—Rash—Ramipril—type 2 diabetes mellitus	8.1e-06	0.000116	CcSEcCtD
Bortezomib—Dermatitis—Ramipril—type 2 diabetes mellitus	8.09e-06	0.000115	CcSEcCtD
Bortezomib—Headache—Ramipril—type 2 diabetes mellitus	8.05e-06	0.000115	CcSEcCtD
Bortezomib—Nausea—Ramipril—type 2 diabetes mellitus	7.63e-06	0.000109	CcSEcCtD
Bortezomib—PSMB2—Gene Expression—AKT1—type 2 diabetes mellitus	7.36e-07	1.3e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GNB3—type 2 diabetes mellitus	7.35e-07	1.3e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARGC1A—type 2 diabetes mellitus	7.35e-07	1.3e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP2E1—type 2 diabetes mellitus	7.32e-07	1.29e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—HMOX1—type 2 diabetes mellitus	7.32e-07	1.29e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	7.3e-07	1.29e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	7.3e-07	1.29e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—type 2 diabetes mellitus	7.3e-07	1.29e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—LPL—type 2 diabetes mellitus	7.3e-07	1.29e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—type 2 diabetes mellitus	7.3e-07	1.29e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—type 2 diabetes mellitus	7.25e-07	1.28e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP1A2—type 2 diabetes mellitus	7.24e-07	1.28e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SLC2A1—type 2 diabetes mellitus	7.24e-07	1.28e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CAT—type 2 diabetes mellitus	7.22e-07	1.28e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ADCY5—type 2 diabetes mellitus	7.15e-07	1.26e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	7.12e-07	1.26e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GPX1—type 2 diabetes mellitus	7.12e-07	1.26e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	7.11e-07	1.26e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP3A4—type 2 diabetes mellitus	7.06e-07	1.25e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	7.03e-07	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOB—type 2 diabetes mellitus	7.01e-07	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	7e-07	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	7e-07	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GCG—type 2 diabetes mellitus	6.94e-07	1.23e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SLC2A4—type 2 diabetes mellitus	6.94e-07	1.23e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CD36—type 2 diabetes mellitus	6.94e-07	1.23e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.88e-07	1.22e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.88e-07	1.22e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.88e-07	1.22e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	6.86e-07	1.21e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPP2CA—type 2 diabetes mellitus	6.85e-07	1.21e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—type 2 diabetes mellitus	6.84e-07	1.21e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PSMD6—type 2 diabetes mellitus	6.84e-07	1.21e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SREBF1—type 2 diabetes mellitus	6.84e-07	1.21e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SNAP25—type 2 diabetes mellitus	6.84e-07	1.21e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—type 2 diabetes mellitus	6.83e-07	1.21e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—type 2 diabetes mellitus	6.83e-07	1.21e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—type 2 diabetes mellitus	6.83e-07	1.21e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTM1—type 2 diabetes mellitus	6.82e-07	1.21e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—type 2 diabetes mellitus	6.81e-07	1.2e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—type 2 diabetes mellitus	6.8e-07	1.2e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.79e-07	1.2e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—type 2 diabetes mellitus	6.78e-07	1.2e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.75e-07	1.19e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.75e-07	1.19e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.75e-07	1.19e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—type 2 diabetes mellitus	6.74e-07	1.19e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CTGF—type 2 diabetes mellitus	6.72e-07	1.19e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—LPL—type 2 diabetes mellitus	6.69e-07	1.18e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	6.66e-07	1.18e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.65e-07	1.18e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	6.61e-07	1.17e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MTHFR—type 2 diabetes mellitus	6.57e-07	1.16e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	6.56e-07	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GNB3—type 2 diabetes mellitus	6.56e-07	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARGC1A—type 2 diabetes mellitus	6.56e-07	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ADCY5—type 2 diabetes mellitus	6.55e-07	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HMOX1—type 2 diabetes mellitus	6.53e-07	1.15e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GPX1—type 2 diabetes mellitus	6.53e-07	1.15e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	6.51e-07	1.15e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3R1—type 2 diabetes mellitus	6.51e-07	1.15e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—NOS3—type 2 diabetes mellitus	6.51e-07	1.15e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARA—type 2 diabetes mellitus	6.45e-07	1.14e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CAT—type 2 diabetes mellitus	6.45e-07	1.14e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CD36—type 2 diabetes mellitus	6.36e-07	1.12e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.31e-07	1.12e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.28e-07	1.11e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPP2CA—type 2 diabetes mellitus	6.28e-07	1.11e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	6.26e-07	1.11e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOB—type 2 diabetes mellitus	6.26e-07	1.11e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.25e-07	1.11e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AGT—type 2 diabetes mellitus	6.25e-07	1.1e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	6.19e-07	1.09e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	6.17e-07	1.09e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CALM1—type 2 diabetes mellitus	6.14e-07	1.09e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOE—type 2 diabetes mellitus	6.12e-07	1.08e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTM1—type 2 diabetes mellitus	6.09e-07	1.08e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOA1—type 2 diabetes mellitus	6.05e-07	1.07e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	6.04e-07	1.07e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	6.04e-07	1.07e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	6.04e-07	1.07e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	6.04e-07	1.07e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	6.03e-07	1.07e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MTHFR—type 2 diabetes mellitus	6.03e-07	1.07e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	6.01e-07	1.06e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	6e-07	1.06e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.98e-07	1.06e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	5.98e-07	1.06e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—LPL—type 2 diabetes mellitus	5.97e-07	1.06e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	5.96e-07	1.05e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—type 2 diabetes mellitus	5.95e-07	1.05e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	5.93e-07	1.05e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	5.93e-07	1.05e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	5.93e-07	1.05e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	5.92e-07	1.05e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARA—type 2 diabetes mellitus	5.91e-07	1.05e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	5.89e-07	1.04e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	5.89e-07	1.04e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	5.89e-07	1.04e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	5.88e-07	1.04e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	5.85e-07	1.03e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ADCY5—type 2 diabetes mellitus	5.85e-07	1.03e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GPX1—type 2 diabetes mellitus	5.83e-07	1.03e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	5.76e-07	1.02e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	5.75e-07	1.02e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AGT—type 2 diabetes mellitus	5.73e-07	1.01e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—type 2 diabetes mellitus	5.72e-07	1.01e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—type 2 diabetes mellitus	5.72e-07	1.01e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—type 2 diabetes mellitus	5.72e-07	1.01e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	5.71e-07	1.01e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	5.68e-07	1e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CD36—type 2 diabetes mellitus	5.68e-07	1e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—type 2 diabetes mellitus	5.64e-07	9.97e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CALM1—type 2 diabetes mellitus	5.63e-07	9.95e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOE—type 2 diabetes mellitus	5.61e-07	9.92e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPP2CA—type 2 diabetes mellitus	5.61e-07	9.91e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	5.6e-07	9.9e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	5.55e-07	9.81e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	5.55e-07	9.8e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	5.5e-07	9.71e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	5.45e-07	9.63e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	5.38e-07	9.51e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MTHFR—type 2 diabetes mellitus	5.38e-07	9.51e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	5.36e-07	9.48e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	5.33e-07	9.43e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARG—type 2 diabetes mellitus	5.33e-07	9.42e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	5.31e-07	9.4e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	5.28e-07	9.33e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	5.28e-07	9.33e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	5.28e-07	9.33e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARA—type 2 diabetes mellitus	5.28e-07	9.33e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—INS—type 2 diabetes mellitus	5.23e-07	9.24e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	5.22e-07	9.23e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—type 2 diabetes mellitus	5.19e-07	9.17e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—type 2 diabetes mellitus	5.19e-07	9.17e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—type 2 diabetes mellitus	5.19e-07	9.17e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	5.18e-07	9.16e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	5.18e-07	9.15e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	5.16e-07	9.11e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	5.14e-07	9.08e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	5.11e-07	9.04e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.11e-07	9.04e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—type 2 diabetes mellitus	5.11e-07	9.04e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	5.11e-07	9.04e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AGT—type 2 diabetes mellitus	5.11e-07	9.04e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	5.09e-07	9e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	5.03e-07	8.89e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CALM1—type 2 diabetes mellitus	5.03e-07	8.88e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	5.02e-07	8.88e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOE—type 2 diabetes mellitus	5.01e-07	8.85e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOA1—type 2 diabetes mellitus	4.95e-07	8.75e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	4.95e-07	8.75e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	4.9e-07	8.67e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	4.89e-07	8.64e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	4.88e-07	8.62e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	4.85e-07	8.58e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	4.83e-07	8.54e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	4.81e-07	8.51e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	4.79e-07	8.47e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—type 2 diabetes mellitus	4.79e-07	8.47e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.78e-07	8.46e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.78e-07	8.46e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.78e-07	8.46e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	4.78e-07	8.44e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	4.78e-07	8.44e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	4.74e-07	8.38e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.72e-07	8.34e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	4.7e-07	8.31e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	4.66e-07	8.24e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	4.66e-07	8.23e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	4.62e-07	8.17e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	4.61e-07	8.14e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3R1—type 2 diabetes mellitus	4.58e-07	8.1e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NOS3—type 2 diabetes mellitus	4.58e-07	8.1e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	4.58e-07	8.1e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	4.58e-07	8.09e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	4.58e-07	8.09e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	4.57e-07	8.07e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	4.56e-07	8.06e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	4.55e-07	8.05e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	4.54e-07	8.03e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	4.51e-07	7.98e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	4.42e-07	7.82e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	4.39e-07	7.77e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	4.37e-07	7.72e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARG—type 2 diabetes mellitus	4.36e-07	7.71e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—INS—type 2 diabetes mellitus	4.28e-07	7.56e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	4.2e-07	7.43e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	4.2e-07	7.43e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—type 2 diabetes mellitus	4.19e-07	7.41e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	4.19e-07	7.41e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	4.11e-07	7.27e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	4.01e-07	7.09e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	3.98e-07	7.04e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	3.98e-07	7.03e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	3.95e-07	6.98e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.95e-07	6.98e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	3.94e-07	6.96e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	3.93e-07	6.94e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—type 2 diabetes mellitus	3.92e-07	6.93e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	3.92e-07	6.92e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	3.9e-07	6.9e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	3.9e-07	6.9e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	3.88e-07	6.85e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	3.86e-07	6.82e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	3.84e-07	6.8e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	3.76e-07	6.65e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3R1—type 2 diabetes mellitus	3.75e-07	6.63e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NOS3—type 2 diabetes mellitus	3.75e-07	6.63e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	3.66e-07	6.47e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	3.61e-07	6.38e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	3.59e-07	6.35e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	3.58e-07	6.32e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	3.52e-07	6.22e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	3.51e-07	6.2e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	3.45e-07	6.1e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	3.45e-07	6.1e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—type 2 diabetes mellitus	3.43e-07	6.07e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	3.42e-07	6.05e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	3.42e-07	6.05e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	3.41e-07	6.03e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	3.4e-07	6.01e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	3.37e-07	5.96e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	3.33e-07	5.89e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	3.23e-07	5.72e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	3.17e-07	5.61e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	3.16e-07	5.58e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	3.13e-07	5.53e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	3.07e-07	5.43e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	3.06e-07	5.4e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	3.02e-07	5.34e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	3.01e-07	5.32e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—type 2 diabetes mellitus	2.99e-07	5.29e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	2.98e-07	5.26e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	2.92e-07	5.17e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	2.92e-07	5.17e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	2.67e-07	4.73e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	2.62e-07	4.64e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	2.57e-07	4.55e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.36e-07	4.17e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	2.26e-07	3.99e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	2.26e-07	3.99e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—type 2 diabetes mellitus	2.11e-07	3.73e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.06e-07	3.65e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	1.93e-07	3.42e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—type 2 diabetes mellitus	1.72e-07	3.05e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	1.59e-07	2.8e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	1.57e-07	2.78e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	1.34e-07	2.38e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.04e-07	1.83e-06	CbGpPWpGaD
